HOME  |  CONTACT  
  spi2012  
 
sachs associates   SPI 2012 Science, Partnering, and Investment Forum:
Gateway for the Global Life Sciences
    21st – 22nd May 2012 • Palm Beach County Convention Center, Florida
 
  spi2012  
 
 
Register Now
 
Register
To Exhibit
 
Register
To Present
 
sachs sachs sachs sachs sachs sachs sachs sachs
Palm Beach County Convention Center
 
sachs sachs
 
sachs
Host Sponsor
bio florida
“BioFlorida is very pleased to be the host sponsor for the Science, Partnering, and Investment forum put on by Sachs Associates. This event will bring investors and partnering executives from around the globe to Florida, and continue to highlight the strength of Florida as a growing leader in the global life sciences.” Russell Allen,
President and CEO
of BioFlorida
 
PRESENTING COMPANIES INCLUDE:
AxoGen Inc.
BetaStem Therapeutics
Cardium Therapeutics
Cobra Biologics
Cytonics Corporation
DSM Biologics
Epizyme
Etubics Corporation
GLG Pharma
Heat Biologics Inc
Hepregen Corporation
Heptares Therapeutics
immatics biotechnologies
ImmunoVaccine Technologies Inc.
Inovio Pharmaceuticals
Intra-Cellular
Therapies Inc.

Lifeblood Medical, Inc.
MedGenesis
Therapeutix Inc.

MEDomics
Metabolon Inc.
MolecularMD
Mucosis BV
Myriad Genetics Inc.
Northern Biotechnologies
Novian
Organovo
Oxford BioTherapeutics
Plantform Corporation
Select BioVenture Partners
United Technologies
University of Pittsburg
VBI Vaccines
Xcovery
Zomanex

 

 

Keynote Speakers – Click on name to show/hide profiles

Elona Baum, General Counsel & Vice President of Business Development, CIRM

elona baum

Elona Baum is the General Counsel and Vice President of Business Development for the California Institute for Regenerative Medicine (CIRM). She is an experienced attorney with more than 20 years of practice, mostly in the life sciences and drug development field. As a member of CIRM’s executive team, Ms. Baum is responsible for the strategic initiatives of the agency, as well as overall management of the legal function. Prior to joining CIRM, Ms. Baum held the positions of Associate General Counsel and later Director of Regulatory Policy and Strategy at Genentech, Inc. (1996 to 2009). Prior to Genentech, she practiced law at private firms. Ms. Baum received her BA in Economics from the University of California and her JD from the University of San Francisco School of Law. She served as an extern for Justice John A. Arguelles, California Supreme Court.

Jeremy Ring, Senator, The Florida Senate

jeremy ring

Jeremy Ring was raised in Massachusetts and after high school attended Syracuse University, graduating in 1992. After college, Mr. Ring moved to New York City joining with a small group of entrepreneurs who created Yahoo!. Opening the first east coast Yahoo! office out of his New York City apartment, he was instrumental in growing sales to over $1 billion in just five years. Jeremy’s position gave him access to Fortune 500 companies throughout the world, promoting the power of bold ideas.

After leaving Yahoo in 2001, Mr. Ring relocated to Florida, where he immediately became involved in his community. He co-founded a charity, SUPERB, whose mission is to teach children social and behavioral skills in order to create a safe school environment enabling students to enjoy school and learn effectively.

Jeremy still remains very active in the business world. His most recent venture is a ground-breaking medical company, Mercurian which focuses on autism and other related disorders using predictive modeling that helps parents track their child’s behavior and reactions to their environment, leading to better care.

In the Florida Senate, Jeremy serves as the Chairman of the Governmental Accountability and Oversight committee, which oversees the Florida Pension Fund, the State Board of Administrations and other government entities in the State of Florida. He is also a member of the Florida Statewide Passenger Rail Commission. Senator Ring has sponsored and passed several major bills including bills that created SunRail, (a high speed passenger rail service) and modernized Florida’s State Pension System.

Senator Ring lives in Parkland and is the proud father of four children, Elijah, Levi, Eliana, and Galit.

Sheridan G. Synder, Chairman, President and CEO, Biocatalyst International

sheridan G synder

Sheridan G. Snyder is an entrepreneur with over forty years of experience, and a major figure in today's biotechnology industry.

Mr. Snyder graduated from the University of Virginia in 1958 with a BA, majoring in Romance Languages. His first company was Cambridge Mailing Machines, in 1964 that manufactures high speed envelope inserting machines.

Since then Mr. Snyder has subsequently founded 13 companies. These include Genzyme, based in Cambridge , Massachusetts , which now has a market cap of over $18 billion. Mr. Snyder's most recent venture was Upstate, a biotechnology company based in Charlottesville , Virginia which was recently sold to Serologicals Corp.

In 1971 Mr. Snyder also founded a packaging company, Instapak, which markets a new form of industrial packaging whereby liquid urethane is injected into a package and expands to 120 times its original volume in 15 seconds to form a complete protective barrier for heavy, fragile, technical equipment. It is now the largest division of Sealed Air Corp.

Biocatalyst International is the most recent of Mr. Snyder's business enterprises. It was founded with Mr. Snyder's vision of bridging the gap between countries that have brilliant science and the United States.

Confirmed Speakers – Click on name to show/hide profiles

Adam Buckley, VP, Operations & Project Management,VBI Vaccines

Adam Buckley

In 2001, Adam Buckley's helped establish VBI. His efforts included attracting seed capital to VBI, developing its first business plan, protecting intellectual property and structuring the company. He had an active role in the company’s Series A financing, raising $35.7 million (U.S.), and has led several key technology acquisitions for the company, including the acquisition of Epixis S.A and the eVLP platform in 2011. Mr. Buckley obtained his M.B.A. and Bachelor of Science in Biology and Psychology at McMaster University in Canada. Prior to joining VBI, he built experience in project management and corporate development at Riverview Hospital in Coquitlam, British Columbia, and at the Children’s Hospital of Eastern Ontario in Ottawa, Ontario.

Alan Heldman, Clinical Chief of Cardiology, University of Miami

Alan Heldman's profile will be online shortly.

Alan Moore, CEO, BetaStem Therapeutics

Alan Moore PhD joined BetaStem Therapeutics as CEO in late December 2011. After a highly prominent career in research and development in both Small and Big Pharma (Procter & Gamble), navigating ten compounds through from the initial research idea stage to clinical trials, three to Phase II, two to Phase III, including ACE inhibitors, skeletal muscle relaxants, inotropes, anti‐arrhythmics, acute cardiac care products, and nasal decongestants (P&G). Alan filed three NDAs and one European filing: one for arrhythmia treatment, one for orphan indication for gout, one approved antiarrhythmic drug in Europe (Brinavess,TM, vernakalant Cardiome) and one approved NDA for a diagnostic for high BP (Sarenin, iv P&G). He has successfully managed multi‐million dollar budgets, led L&A activities culminating in many successful deals, such as, acquisition by P&G Pharmaceuticals of Alexion’s complement inhibitor for CABG and acute MI. He partnered deals with Japanese firms, such as Procter & Gamble’s antiarrhythmic compound with Tanabe Seiyaku. Alan’s skill and enthusiasm (including being an expert guitar player since youth) has been a great boost to all of us at BetaStem Therapeutics, a rapidly emerging adult stem cell therapy company in the process of completing an IND for a first in man clinical trial.

Alison Urkowitz, VP of Research Operations, Michael J. Fox Foundation

Alsion Urkowitz

Alison Urkowitz joined the Foundation in 2005.

As Vice President, Research Operations, Alison manages a team of project managers, strategic professionals and grant administrators who stay closely linked to the Parkinson’s research community in order to develop and drive an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease. These components ensure that MJFF research priorities reflect and best serve the ultimate needs of patients. Alison regularly interacts with internal and external researchers as well as business development, contracting and licensing experts to identify promising initiatives to support in order to implement the most effective mechanisms for driving them forward. In addition to overseeing the operations of all research activities for the Foundation, she specifically supports the Foundation’s priority LRRK2 and dyskinesia related activities.

Ms. Urkowitz earned a Bachelor of Arts from Tufts University and a Master of Public Administration focusing on public and non-profit management from New York University’s Robert F. Wagner School of Public Service. Prior to joining the Foundation, Alison spent five years working in the media buying departments of Zenithmedia and Initiative Media, negotiating and managing the national television advertising campaigns of various global clients.

Anne Altemeyer, Executive Director Business Development & Licensing,
Novartis Pharmaceuticals Corporation

Anne Altemeyer is an Executive Director in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her responsibilities are to in-license or acquire Oncology assets that can further strengthen or complement the Novartis Oncology portfolio. In this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing alliances.

Anne has 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of Novartis in 2004 as a Project Leader. In this role, she led numerous multidisciplinary International Project Teams through the generation and implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked as a Project Manager at Merck & Co. for over 3 years and as a Visiting Research Scientist for 2 years.

Anne received her MS and her PhD in Molecular Immunology from the University Louis Pasteur in Strasbourg, France. She then performed a postdoctoral fellowship at New York University School of Medicine, New York, USA, and subsequently became a Research Associate at Cornell University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.

Bard Geesaman, Managing Director, MPM Capital

Bard Geesaman

Dr Bard Geesaman began working with MPM in 2001 as part of the management team for the portfolio company Elixir Pharmaceuticals. In 2006 he became a venture partner at MPM and co-founded Solasia, a specialty pharmaceutical company in Asia developing oncology products. Prior to working at MPM, Dr. Geesaman was a General Partner at F2 Ventures, a U.K. based investment firm where he managed the private investments. Dr. Geesaman received his Ph.D. in systems biology from M.I.T., his M.D. from Harvard Medical School, and his B.S. in neurobiology from U.C. Berkeley. He is board certified in internal medicine and did his residency at Massachusetts General Hospital.

Bernadette C. Fendrock, President and CEOHepregen Corporation

Bernadette Fendrock

Bernadette C. Fendrock is co-founder, president and CEO of Hepregen. Ms. Fendrock comes to Hepregen with twenty five years of commercial experience in the life sciences industry. As vice president at Genzyme Corporation, Ms. Fendrock was responsible for the commercial planning and market launch of biosurgical products to treat post operative adhesions. Prior to Genzyme, Ms. Fendrock held positions as director of business development, Somatix, Inc., a start-up gene therapy company, and project manager, Genetics Institute (now Wyeth). Ms. Fendrock also has been a business consultant for the Harvard-MIT Division of Health Sciences and Technology and the Biomedical Enterprise Program (a collaboration with The Sloan School at MIT) and Acusphere, Inc. Ms. Fendrock holds a B.A. degree with a major in molecular biology from Wellesley College, a S.M. degree from MIT in interdisciplinary science and an M.B.A. from The Wharton School of the University of Pennsylvania.

Bernard Siegel, Executive Director, Genetics Policy Institute

Bernard Siegel's profile will be online shortly.

Beth Jacobs, Managing Partner, Excellentia Global Partners

Beth Jacobs

Beth Jacobs is the founding Partner of Excellentia Global Partners, a global life science-focused investment bank in New York. In her role overseeing origination and execution of private placements, she has an active dialogue with corporations, financial sponsors, venture capital groups, hedge funds and mutual funds. Beth is also involved in cross border M&A, Licensing and Partnering in the life sciences arena.

Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. On the advisory side, she was most recently Managing Director / Partner of BIO-IB, a life science boutique investment bank in New York. Prior to 2003, Beth was Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 7 years. While at ING and Furman, she originated and executed many public and private financings for a wide variety of issuers throughout Asia, including the largest 144A equity offering for a real estate company in the Philippines (Empire East Land’s $210MM initial public offering). She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers.

In the corporate sector, Beth was most recently Senior Vice President for Laureate Education Inc. (NASDAQ: LAUR), a $3 billion market cap company in the education sector. She worked across all business units in a corporate development role with a distinct focus on identifying and executing on opportunities in China. Notable transactions included exploring alternatives for Wall Street Institute (a company owned by Laureate and later acquired by the Carlyle Group); initiating and executing a joint venture with Jinjiang Group, the largest hotel group in China; and finding new acquisition and development opportunities for Les Roches, Laureate’s hotel management training business based in Crans Montana, Switzerland.

Beth received an MBA from American University in Washington, DC in conjunction with the School of Foreign Service, a BA, cum laude, from Boston College, and also studied at the Centre d’Etudes Internationale in Geneva, Switzerland.

Beth serves as Vice Chairman of the Friends of the Budapest Festival Orchestra Board, Director of EF Foundation (Stockholm and Cambridge, MA), Global Ambassador for Susan G. Komen Foundation and Director of William J. von Liebig Medical Research Foundation.

Bharatt Chowrira, CEO, Addex Pharmaceuticals

Bharatt Chowrira's profile will be online shortly.

Carlos Garrido, Business Development Director - Latin America, AstraZeneca

Carlos Garrido's profile will be online shortly.

Christopher Reinhard, Chairman of the Board, CEO, President and Treasurer,
Cardium Therapeutics

Christopher Reinhard

Christopher Reinhard's is a co-founder of Cardium and has served as a director and the Chief Executive Officer, President and Treasurer of Cardium since its inception in December 2003. Mr. Reinhard has also served as a director and the Chief Executive Officer and Treasurer of InnerCool Therapies, Inc. since March 2006, and as a director and Chief Executive Officer and President of Tissue Repair Company since August 2006, wholly-owned subsidiaries of Cardium. Mr. Reinhard has focused on the commercial development of cardiovascular growth factor therapeutics. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., and served as a director (from 1995) and President (from 1999) of Collateral until the completion of its acquisition by Schering AG Group, Germany (Schering) in 2002. He continued as Chief Executive of Collateral through December 2004. Mr. Reinhard played a major role in effecting Collateral’s initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral to Schering. Mr. Reinhard has also been Executive Chairman (since 2004) of Artes Medical, Inc., a publicly-traded medical technology company. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus, Instrumentation Laboratory and IMED Corporation. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.

Claudia Hillinger, President for Institute Development, Max Planck Florida Institute

Claudia Hillinger

Under the direction of Dr Claudia Hillinger Vice President for Institute Development, the new Max Planck Florida Institute established itself in temporary quarters on the Florida Atlantic University Campus in Jupiter, Florida. Plans for its 100,000-square-foot research building are in place and the schedule is set for a fully operational building in late summer of 2012. With a focus on neurosciences, the Max Planck Florida Institute’s mission is to integrate biology and technology to provide fundamental advances in our understanding of the functional organization of the brain.

As President of the Max Planck Florida Foundation, Dr. Hillinger provides leadership to an expanded community relations and public outreach program, including all phases of institutional advancement and fund raising initiatives.

Dr. Hillinger joined the Max Planck Society in 1998 and was responsible for Institute development before becoming the research coordinator and head of the Central Scientific Laboratories and Technical Facilities for the Max Planck Institute of Biogeochemistry in Jena, Germany. Previously, she held the position of research group leader at the Institute of Botany and Microbiology at the Technical University of Munich (TUM), and served as assistant to both the American Deputy Director and the German Program Director at the American Embassy in Bonn, Germany and Amerika Haus München.

Dr. Hillinger received her bachelor’s degree in English and Spanish from the Academy of Foreign Languages in Munich; a master’s of science degree in biology from TUM; and her doctorate in biology from the Institute of Botany and Microbiology at TUM.

Dr. Hillinger currently serves on the board of directors for the Florida Research Consortium; BioFlorida; Southeast BIO (SEBIO); Northern Palm Beach Chamber of Commerce; and the Quantum House. She is a member of the Florida Atlantic University’s Strategic Planning Committee. She serves on the Advisory Board of Professional Science Masters (PSM) Program that provides guidance to the Florida Council of Graduate Deans and is also a member on the Advisory Council for the Banner Center of Life Sciences of Palm Beach State College. She is an active member of the Palm Beach Flagler Rotary Club, and was recently recognized by the South Florida Business Journal as one of southeast Florida’s most influential business women.

Dan Grau, President, Heptares Therapeutics

Dan Grau

Dan Grau is a biotech executive with over 15 years of experience developing, partnering, and commercializing life science products and technologies. He is currently President of Heptares Therapeutics, the leading GPCR drug discovery company, and serves on the Product Advisory Board of Concert Pharmaceuticals and as an advisor to Nimbus Discovery. Previously, Dan was President and CEO of Cortria Corporation, a venture-backed clinical-stage company focused in cardiovascular disease, and Chief Operating Officer of CombinatoRx, Inc., a public biotech company (today Zalicus) focused primarily in pain and inflammation. Earlier in his career, he worked with Pharmacia Corporation (now Pfizer) as a business consultant focused on the commercialization of Celebrex™, Mirapex™, and Detrol™, and was Director of Marketing and Business Development for a healthcare information technology startup. Dan earned his BA with High Honors in English from Davidson College, where he held a Charles A. Dana Honor Scholarship, and received his MPhil in Philosophy from Yale University, where he held an Andrew J. Mellon Fellowship in the Humanities.

David Day, Director, Office of Technology Licensing, University of Florida

David Dayr

David L. Day joined the Office of Technology Licensing at the University of Florida as Director on April 2, 2001, where he oversees the commercialization efforts for UF through licensing, incubation and related activities. Mr. Day serves on the following Board of Directors & Executive Committees: BioFlorida, the Florida Research Consortium and Southeastern Bio Investors Forum. Mr. Day also serves as Vice-Chair of the Board of Directors and Principal Investigator for the Florida Institute for the Commercialization of Public Research. He is Co-Chair of Innovation Gainesville, UF Center for Pharmacometrics and Systems Pharmacology Strategic Advisory Group Member, and an Enterprise Florida Innovations & Entrepreneurship Task Force Member. The University of Florida is the top-performing public institution at transferring its research to the marketplace, according to a study by the Milken Institute. In a report by the California-based economic think tank titled “Mind to Market: A Global Analysis of University Biotechnology Transfer and Commercialization,” UF ranked fifth overall on the Institute’s University Technology Transfer and Commercialization Index. UF’s Office of Technology Licensing annually executes about 75 licenses and options and is involved in the creation of about 10-15 new startups based on UF technologies. In this latest fiscal year, UF spinoffs raised more than $200 million of investment capital.

Dominique Pahud, Director in Advancing Innovation, Kauffman Foundation

Dominque Pahud's profile will be online shortly.

Eduardo Emrich Soares, President and CEO, Fundacao Biominas Brasil

Eduardo Emrich Soares

Eduardo Emrich Soares is the CEO and President of Biominas Brazil since August 2003. Biominas Brasil is a private institution focused on creating business in life sciences in Brazil. Until recently, he was also the CEO and member of the board of Alvos Biotech, a start-up company dedicated to the development of bioproducts (Alvos was sold to Ourofino Agronegócios in July 2010).

He is member of the Board of Directors of Linhagen and Biocancer, used to be Board member of other Life Science companies, as Prodimol (sold to Inverness Group), and is a representative of the industry in several initiatives aimed at developing the Life Science sector in Brazil.

He has over 15 years of experience in structuring and managing companies, licensing in and out of academic technologies, project and business management and international business in life sciences. His network includes the main national and international leaders from various areas of Life Sciences.

Eduardo is a biologist with emphasis in Biochemistry and Molecular Biology, graduated from Federal University of Minas Gerais (UFMG – Belo Horizonte, MG), postgraduate degree in Financial Administration from Fundação Dom Cabral (FDC – Belo Horizonte, MG) and in Business Management Fundação Getúlio Vargas (FGV – Belo Horizonte, MG).

Ekaterina Smirnyagina, Venture Partner, Alta Partners

Ekaterina Smirnyagina

Ekaterina Smirnyagina joined Alta in 2002 and focuses on European investment opportunities. She currently represents Alta on the board of directors of Cerenis Therapeutics and Kiadis Pharma. She also led Alta’s investment in Ablynx.

Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology company, where she negotiated a number of licensing agreements and strategic partnerships. Prior to Genset, Katya was a manager with the Mitchell Madison Group, a global management-consulting firm, from 1997 to 2000.

She obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers.

Elizabeth Bachert, Senior Director, Worldwide Business Development, Pfizer Inc.

Elizabeth Bachert is a Sr. Director, Worldwide Business Development at Pfizer in Groton, CT, where she has supported business development activities for the past 10 years. She is currently responsible for the search and evaluation of clinical stage oncology business opportunities for Pfizer’s Oncology Business Unit. She has contributed to several oncology-focused business transactions including collaborations, licenses, out-licenses, mergers and acquisitions. Elizabeth began her career at Pfizer in the Global R&D operations as a Research Scientist in the Drug Metabolism Department, where she led the design and conduct of preclinical pharmacokinetic and pharmacodynamic studies for projects in the cancer, respiratory, immunology, inflammation, and infectious diseases areas. Elizabeth holds a BS and PhD in Pharmaceutics from the University at Buffalo.

Elizabeth Fenjves, Head of Tech Transfer, Univesity of Miami

Elizabeth Fenjves' profile will be online shortly.

Elona Baum, General Counsel & Vice President of Business Development, CIRM

elona baum

Elona Baum is the General Counsel and Vice President of Business Development for the California Institute for Regenerative Medicine (CIRM). She is an experienced attorney with more than 20 years of practice, mostly in the life sciences and drug development field. As a member of CIRM’s executive team, Ms. Baum is responsible for the strategic initiatives of the agency, as well as overall management of the legal function. Prior to joining CIRM, Ms. Baum held the positions of Associate General Counsel and later Director of Regulatory Policy and Strategy at Genentech, Inc. (1996 to 2009). Prior to Genentech, she practiced law at private firms. Ms. Baum received her BA in Economics from the University of California and her JD from the University of San Francisco School of Law. She served as an extern for Justice John A. Arguelles, California Supreme Court.

Eric Botton, Head of Diagnostics, Metabolon, Inc.

Eric Botton's profile will be online shortly.

Eric Michael David, CSO, Organovo Inc.

Eric Michael David's profile will be online shortly.

Erich Mohr, Chairman and CEO, MedGenesis Therapeutix Inc.

Erich Mohr

Dr Erich Mohr, a Professor of Medicine and Psychology at the University of Ottawa until 1997 has over 25 years of experience in experimental therapeutics of CNS disorders. Dr. Mohr received his Ph.D. in Neuropsychology from the University of Victoria in 1982. He became a Fogarty Fellow at the National Institutes of Health in 1983 and completed his Clinical Fellowship Training in Experimental Therapeutics at the NIH in 1989. He has chaired and /or served on several regulatory advisory panels for the approval of new products for the treatment of neurodegenerative disease and is the former Chairman and Chief Executive Officer of CroMedica Global Inc.,(merged with PRA International in 2002) a full service CRO with a strong focus on Central Nervous System Disorders which became a global corporation with over 550 employees and offices in 5 continents. After a merger with PRA International in 2002, the newly combined company grew to over 3000 employees world-wide and became a publically listed company on NASDAQ. Dr. Mohr has since co-founded several companies in the Life Sciences space, with a combined estimated market cap of over $2 billion.

Dr. Mohr founded MedGenesis Therapeutix Inc. in 2006. MedGenesis Therapeutix Inc. is a leader in the area of Convection Enhanced Delivery (CED), the introduction of therapeutic agents directly into the Central Nervous System, with its lead product GDNF, a potential definitive treatment of Parkinson’s Disease commencing Phase 2 clinical trials in early 2012.

Fintan Walton, CEO and FounderPharma Ventures

Fintan Walton's profile will be online shortly.

Florian Schodel, Owner, Philimune LLC

Florian Schodel's profile will be online shortly.

Frank D Stonebanks, Chief Commercial Officer, Ontario Institute for Cancer Research
(OICR)

Frank D Stonebanks' profile will be online shortly.

Frank R Jones, CEO and President, Etubics Corporation

Frank R Jones' profile will be online shortly.

Gerry Brunk, Managing Director, Lumira Capital Corp

Gerry Brunk

Gerry Brunk is a Managing Director at Lumira Capital, a life sciences venture capital firm with $400 million under management. With over 20 years of investment, consulting and entrepreneurial experience, he has helped build life science companies at all stages of development.

Before joining Lumira Capital in 2002 to establish the firm’s Boston office, Mr. Brunk was an entrepreneur in the life science sector, founding and serving in a variety of management and board capacities at several venture capital-funded companies. Earlier in his career he was an engagement manager in the health care practice of The Boston Consulting Group, where he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, product licensing, R&D productivity, new product introductions, acquisitions, and post-merger integration. Gerry began his career as a member of the investment banking group of Credit Suisse First Boston where his clients included public and private health care companies.

He holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics.

Mr. Brunk’s current or past board roles and investment responsibilities include Archemix, Cardiac Dimensions, MAKO Surgical (NASDAQ: MAKO), NephroGenex, Pharmasset (acquired by Gilead Sciences), PharmAthene (AMEX: PIP), and Targanta Therapeutics (now NASDAQ: MDCO). He also serves on the board of directors of Southeast BIO.

Goro Takeda, Venture Partner, Sofinnova Ventures

Goro Takeda's profile will be online shortly.

Gregg Fields, Director of Research and Full Member,
Torrey Pines Institute for Molecular Studies

Gregg Fields' profile will be online shortly.

Gregory Freitag, Chief Financial Officer, AxoGen, Inc.

Gregory Freitag

Gregory Freitag J.D., CPA, was CEO of LecTec Corporation prior to its name change to AxoGen, Inc. and merger with AxoGen Corporation in September 2011. He was cofounder, and continues as a principal, of FreiMc, LLC, a consulting and advisory firm that provides strategic guidance and business development advisory services related to the life sciences and healthcare markets. Prior to founding FreiMc, Greg was the Director of Business Development at Pfizer Health Solutions, a former subsidiary of Pfizer, Inc. and worked for Guidant Corporation in their business development group. Prior to Guidant Corporation, he was the Chief Executive Officer of HTS Biosystems, a biotechnology tools start-up. HTS was a spin-out of technology from Quantech, Ltd., a public point of care diagnostic company, for which Greg was CFO, COO and a director. He started his career practicing corporate/securities law in Minneapolis, Minnesota.

Greg has transaction proficiency across a broad industry spectrum with specific emphasis on Life Science and Healthcare. His background has resulted in extensive worldwide negotiation, business and legal experience, including finance, product marketing/distribution, corporate merger/acquisition, technology/service collaborations, manufacturing and intellectual property licensing. Such skill set blends well with AxoGen as it continues to grow as a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration.

Guilherme Emrich, Chairman of the Boards, Biomm SA and FIR Capital Partners SA

guilherme emrich

Guilherme Emrich was the Chairman of Biobras S.A. prior to forming FIR Capital. Under Guilherme´s leadership, Biobras grew from a start-up to become the world´s 4th largest insulin producer. Among its other achievements, Biobras consistently ranked as one of the top five performing stocks on the Sao Paulo Stock Exchange´s BOVESPA index and was the best performing investment ever made by BNDES, Brazil´s National Economic Development Bank.

Guilherme also played an important role in the formation of the Biominas Foundation, a thriving biotechnology cluster that is the largest in Latin America and one of the largest in the world, comparable to North Carolina´s Triangle Research Park.

Guilherme was nominated by the President of Brazil to serve on the National Council of Science and Technology and is a member of the board of directors of the Dom Cabral Foundation, the leading management development institute for top corporations and entrepreneurs in Brazil.

Guilherme is a former Chairman and Board Member of the International Chamber of Commerce of Brazil, and currently serves as the Honorary Consul of the Republic of Russia in Belo Horizonte. Guilherme also serves as a member of the international Board of Directors of INSEAD in Brazil and on the board of directors of several FIR Capital portfolio companies.

Gwen Melincoff, SVP Business Development, Shire Pharmaceuticals Group plc

Gwen Melincoff's profile will be online shortly.

Henry Appelbaum, President, CEO & Director, Novian Health

Henry Appelbaum's profile will be online shortly.

Irena Melnikova, Director, Prospective and Strategic Initiatives, Sanofi

Irene Melnikova

Irena Melnikova PhD, is a Director of Strategy and External Innovation at sanofi. Prior to joining sanofi, Irena was a Principal in the Life Science team of TVM Capital, a global venture capital firm. At TVM, she was involved in deal origination and new investment opportunity evaluation and actively participated in the management of TVM Capital investments in the United States.

Prior to TVM Capital, she was a member of the biopharma investment banking team at Leerink Swann. She also produced and launched a new series of syndicated reports for the firm. Entitled Future in Focus, these reports provided clients with insight and analysis of business and technology issues shaping corporate and R&D strategies, pipelines and alliances.

Prior to Leerink Swann, Irena was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology market research company.

As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was responsible for running several programs, including Engineered Tissue Constructs, funded by DARPA, and Amyloidoses.

Irena has published over 20 manuscripts in peer-reviewed journals and is a regular contributor to the “Analyst Couch” section of Nature Reviews in Drug Discovery magazine.

J. Joseph Kim, CEO, Inovio Pharmaceuticals Inc

J. Joseph Kim

J. Joseph Kim became the CEO of Inovio Pharmaceuticals with the completion of the company’s merger with VGX Pharmaceuticals in June 2009. Previously, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products for hepatitis and developmental vaccines and therapeutics for HIV/AIDS at Merck & Co. Dr. Kim has published over 100 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels. He has a B.Sc. in Chemical Engineering and Economics from MIT, where he was a U.S. Senate Honors Scholar. He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School

James J. Mulé, Executive VO and Associates Center Director for Translational Research,
Moffitt Cancer Center

James J Mule

James J. Mulé received his post-graduate degrees from the University of Washington and the Fred Hutchinson Cancer Research Center. He then received his formal post-graduate training at the Division of Cancer Treatment, NCI, NIH, and soon became a Senior Investigator there at the Surgery Branch. Dr. Mulé took an 18-month leave as an Adjunct Visiting Professor at Department of Surgery, Stanford University, where he also helped to launch the biotechnology companies SyStemix and Progenesys. He then moved to Michigan as the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Cancer Center. He was also Founding Director of the Immunology Graduate Program, the Maude T. Lane Endowed Professor of Surgery, Department of Surgery, and he was Professor in the Department of Internal Medicine as well. Dr. Mulé is now EVP and ACD for Translational Research and the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment at the Moffitt Cancer Center. He serves on the Board of Directors of Medicine in Need, and is a member of the Scientific/Medical Advisory Board of Aura Biosciences; both selected as 2011 Technology Pioneers by the World Economic Forum, Davos). Dr. Mulé remains a long-standing special government employee to the FDA and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee at FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors. Dr. Mulé’s research group is involved in vaccine strategies and other approaches (e.g., gene therapy) to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mulé has published nearly 200 articles in cancer immunotherapy, and is an NCI-NIH funded investigator continuously for nearly 20 years.

James Rosen, Partner, Intersouth Partners

James Rosen's profile will be online shortly.

Jarett Rieger, Director of OTMC and Associate General Counsel,
H. Lee Moffitt Cancer Center & Research Institute

Jarett Rieger

Jarett Rieger oversees the Office of Technology Management and Commercialization (“OTMC”) at Moffitt Cancer Center. His department is charged with commercializing the cancer related discoveries made at Moffitt Cancer Center ranging from protecting the intellectual property to forging licensing alliances with established companies and startups. In addition, OTMC negotiates on behalf of the Moffitt Cancer Center a wide variety of research and intellectual property agreements. His tenure began at Moffitt Cancer Center in 2004, and he was promoted to Director of OTMC in 2006. Prior to joining Moffitt, Mr. Rieger practiced as a patent attorney at Breed Technologies in Lakeland, Florida.

Mr. Rieger received both his Juris Doctor and Master of Business Administration degrees from Stetson University College of Law in Saint Petersburg, Florida; he received his Bachelor of Arts in Chemistry from Rollins College in Winter Park, Florida. He is admitted to the Florida Bar and is a registered Patent Attorney.

Mr. Rieger is a member of the Association of University Technology Managers, Licensing Executive Society and American Intellectual Property Law Association. He graduated from Leadership Hillsborough in 2010.

Jeffrey Cohen, Director - Healthcare Research, Ladenburg Thalmann & Co, Inc.

Jeffrey Cohen's profile will be online shortly.

Jeff Wolf, Chairman and CEO, Heat Biologics Inc

Jeff Wolf's profile will be online shortly.

Jeremy Ring, Senator, The Florida Senate

jeremy ring

Jeremy Ring was raised in Massachusetts and after high school attended Syracuse University, graduating in 1992. After college, Mr. Ring moved to New York City joining with a small group of entrepreneurs who created Yahoo!. Opening the first east coast Yahoo! office out of his New York City apartment, he was instrumental in growing sales to over $1 billion in just five years. Jeremy’s position gave him access to Fortune 500 companies throughout the world, promoting the power of bold ideas.

After leaving Yahoo in 2001, Mr. Ring relocated to Florida, where he immediately became involved in his community. He co-founded a charity, SUPERB, whose mission is to teach children social and behavioral skills in order to create a safe school environment enabling students to enjoy school and learn effectively.

Jeremy still remains very active in the business world. His most recent venture is a ground-breaking medical company, Mercurian which focuses on autism and other related disorders using predictive modeling that helps parents track their child’s behavior and reactions to their environment, leading to better care.

In the Florida Senate, Jeremy serves as the Chairman of the Governmental Accountability and Oversight committee, which oversees the Florida Pension Fund, the State Board of Administrations and other government entities in the State of Florida. He is also a member of the Florida Statewide Passenger Rail Commission. Senator Ring has sponsored and passed several major bills including bills that created SunRail, (a high speed passenger rail service) and modernized Florida’s State Pension System.

Senator Ring lives in Parkland and is the proud father of four children, Elijah, Levi, Eliana, and Galit.

John Cullity, Principal, Torreya Partners

john cullity

John Cullity works at the New York office of Torreya Partners, a life sciences advisory firm providing services in M&A, licensing, and corporate finance. Previously he was at Sanofi Aventis where he coordinated $3 billion transactions in oncology and diabetes. John led Sanofi Aventis’ strategic pricing department managing the $15 billion portfolio, and placing valuations on the pipeline. He was previously at Schering-Plough in strategic pricing and health economics. John has also worked for AT Kearney, World Bank, WHO and as an internist in UK and Australia. He holds MBA Wharton, MSc (Econs) from LSE, Medical Boards from Royal College of Physicians UK, and medical degree from University of Western Australia.

John M Hyshka, CFO, Phenomenome Disocveries

John M Hyshka's profile will be online shortly.

John Trizzino, Chief Executive Officer and Director, Immunovaccine Inc.

John Trizzino

John Trizzino is a U.S.-based senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax Inc., where he provided strategic direction and successfully negotiated profitable joint venture and licensing agreements, including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts and executing a series of successful commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island University and received his master’s degree in business administration from New York University’s Leonard N. Stern School of Business.

Jordi Esclusa, Managing Partner, AEC Partners

Jordi Esclusa

Jordi Esclusa is a Graduate of major French engineering University (ENSAM), Postgraduate diploma in Bioengineering, MA in Economics. Jordi Esclusa is Founder and Managing Partner at AEC Partners since 1997. He started his career as a Controller for a joint venture in India between Nippon Kokan and Spie Batignolles. Following this experience, Jordi made the jump to consulting where he worked for 9 years with Bossard Consultants and ISO HealthCare. Through multiple assignments, he developed a sound experience in the healthcare industry, working for big pharma companies and HMOs, in Europe, North America and Latin America. In 1997 he co-founded AEC Partners a strategic consulting, business development and advisory services firm specialized in Healthcare and Life Sciences. Jordi works on a regular basis at Corporate, Region and Country levels, on a worldwide scale for big and mid size pharma/Biopharma, biotech companies and VCs. He helps his customers develop and implement growth and investment strategies, such as product value maximization, business development, geographic expansion, portfolio development, market access and product launch strategies. Jordi speaks and works on a regular basis in 6 languages (English, French, Spanish, Portuguese, Italian and Catalan).

Julian Hanak, Commercial Director, Cobra Biologics

Julian Hanak

Julian Hanak re-joined Cobra Biologics in 2011 as the Commercial Director. He previously worked at Cobra for 11 years progressing from Senior Scientist to Director of Production. In 2005 Julian moved to Renovo plc where he attained additional senior management and commercial experience as Senior Vice President of Development. Key responsibilities were product translation into formal development, CMC strategy and the oversight of CMO’s. Julian has a wealth of industry knowledge and drug development experience. Julian also held positions at the National Institute for Medical Research, Bio Products Laboratory Ltd, and AstraZeneca.

Karen King, President, DSM Biologics

Karen King's profile will be online shortly.

Kazumi Shioasaki,Managing Director, Healthcare & Biotechnology, MPM Capital

Kazumi Shioasaki's profile will be online shortly.

Kevin DeGeeter, Director - Healthcare Research, Landenburg Thalmann & Co, Inc.

Kevin DeGeeter is a Director at Ladenburg Thalmann with responsible for equity research coverage of personalized medicine and medical device companies with market capitalization between $50 million and $5 billion. His coverage focuses on molecular diagnostics and medical equipment used in treating oncology, cardiovascular disease, infectious disease and for related research markets. Prior to joining Ladenburg Thalmann, he was an Analyst at Oppenheimer & Co. with responsibility for small cap. molecular diagnostics and biotechnology stocks. He has 10 years of buyside and sellside research experience including positions with J.P Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. Mr. DeGeeter received a BA in economics from Colgate University.

Leslie Molony, Senior Director, Business Development,
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE at Lake Nona

Leslie Molony's profile will be online shortly.

Lisa Rhoads, Managing Director, Easton Capital Investment Group

Lisa Rhoads' profile will be online shortly.

Lorenza Castellon, Health & Biotech Equity Analyst, Equity Development

Lorenza Castellon's profile will be online shortly.

Mark Chalek, Chief, Business Ventures, Beth Israel Deaconess Medical Center /
a Teaching Hospital of Harvard Medical School

Mark Chalek's profile will be online shortly.

Mark Esser, Director, Vaccines and Infectious Disease Translational Medicine, MedImmune

Mark Esser's profile will be online shortly.

Mel Rothberg, Chief Operating Officer, Vaccine and Gene Therapy Institute of Florida Corp.

Mel Rothberg's profile will be online shortly.

Michael Farley, Managing Partner, Valor Management

Michael Farley's profile will be online shortly.

Michael G. McCully, Head of Business Development & Licensing, BioNeurology,
Elan Pharmaceuticals

Michael G. McCully's profile will be online shortly.

Michael Rabson, Partner, Wilson Sonsini Goodrich & Rosati

Michael Rabson's profile will be online shortly.

Michael Weiner, CEO, ElectroHealing Technologies

Michael Weiner's profile will be online shortly.

Nicolas Neckelmann, Vice President, Operations, MEDomics

Nicolas Neckelmann

Nicolas Neckelmann obtained his BSc and PhD in biology at the University of British Columbia and UCLA, respectively. After pursuing postdoctoral research sequencing and analyzing the mitochondrial genome of Leishmania tarentolae in the laboratory of Dr. Larry Simpson at UCLA, Dr. Neckelmann moved to Atlanta for a second postdoc to work in Dr. Douglas Wallace’s lab at Emory University. At Emory he focused on the analysis and characterization of nuclear genes encoding human mitochondrial proteins that play a key role in mitochondrial energy production. Having completed his second postdoc, he continued his research as an Assistant Professor in the Department of Pathology and the Winship Cancer Center at Emory where he worked on the expression of recombinant mitochondrial proteins. In 1991 he moved into the corporate sector where he has held positions in product development and R&D, marketing and sales in companies such as Life Sciences International, QIAGEN, Transgenomic and Scigene. During his 10 years at Transgenomic, Dr. Neckelmann also worked on the development of mitochondrial genetic testing strategies, and subsequent sales of these test in the clinical market. Dr. Neckelmann currently is working as the VP of Operations at MEDomics, LLC in Azusa (in the Los Angeles area), and in this context he continues to pursue genetic testing for mitochondrial disorders.

Pascal Forget, President, Laboratorios Biopas

Pascal Forget's profile will be online shortly.

Patrick Burke, VP Strategic Collaborations, Myriad Genetics Inc.

Patrick Burke's profile will be online shortly.

Paul Higham, Managing Director & CEO, immatics biotechnologies

Paul Higham's profile will be online shortly.

Peter Kalinka, Vice President Biopharmaceuticals, Apotex

Peter Kalinka's profile will be online shortly.

Peter G Nell, Early Licensing, Bayer HealthCare LLC

Peter G Nell's profile will be online shortly.

Philippe Crettex, Sr Vice President, Latin America, MERCK KGaA

Philippe Crettex's profile will be online shortly.

Rafick-Pierre Sekaly, Co-Director and Scientific Director, VGTI

Rafick-Pierre Sekaly's profile will be online shortly.

R Doug Hulse, Executive Director, The Sage Group

R Doug Hulse's profile will be online shortly.

Robert Gould, President & CEO, Epizyme

Robert Gould

Robert Gould joined Epizyme as President and CEO in March, 2010, from the Broad Institute, where he was Director Novel Therapeutics. He has been a member of Epizyme’s board of directors since 2008. He brings extensive experience and a demonstrated track record of success in the pharmaceutical industry.

At the Broad Institute, Robert built and set the strategic vision for Novel Therapeutics and participated in raising more than $100 million in research funding.

Prior to the Broad, Robert held a variety of leadership positions during his 23 years at Merck, culminating in Vice President, Basic Research, WP and Vice President, Worldwide Licensing and External Research. he was instrumental in shepherding more than 20 compounds from discovery into clinical development and market in multiple therapeutic areas. He also spearheaded strategic initiatives for licensing and external research, as well as overseeing the Ophthalmic Worldwide Business Strategy Team.

Robert obtained degrees from Spring Arbor College, Michigan and The University of Iowa and undertook post-doctoral studies at The Johns Hopkins University and has published over 90 peer-reviewed publications and 16 patents.

Robert Silverman, CEO, mtm Roche laboratories AG

Robert Silverman's profile will be online shortly.

Roel Bulthuis, Head, Merck Serono Ventures

Roel Bulthuis' profile will be online shortly.

Rolf Günther, CEO, Bicycle Therapeutics

Rolf Güther

Dr Ralph Günther has more than 25 years of pharmaceutical and biotech industry experience with an extensive background in product development, biologics, and specialty pharmaceuticals. He has held senior positions in marketing, R&D, strategy, operations and general management. Before joining Bicycle he was CEO and COO of Affimed, a recombinant antibody company focusing on bi-specific antibodies. Prior to that he was Vice President and General Manager of the Business Unit Critical Care of Aventis Behring, one of the world’s leading companies specializing in the business of plasma products. He joined Aventis Behring as Vice President of Global Clinical Research and Development in 1996, responsible for successful drug approvals in the US and Europe, and became acting head of world-wide R&D in 2001. Dr. Guenther received his MD and PhD in Physical Chemistry from the University of Mainz, Germany, and completed an Executive Development Program at the University of Pennsylvania’s Wharton School of Business.

Roshnio Dutton, Bioprocess Expert, SNC-Lavalin Pharma

Roshnio Dutton's profile will be online shortly.

Russell Allen, President and CEO, BioFlorida Inc.

Russell Allen's profile will be online shortly.

Saira Ramasastry, Managing Partner, Life Science Advisory

Saira Ramasastry

Saira Ramasastry Managing Partner of Life Sciences Advisory, is a seasoned industry insider with approximately 15 years experience and who has advised on over 80 transactions. Prior to LSA, Saira led emerging biotech coverage at Merrill Lynch for over a decade where she helped establish the leading life sciences franchise on Wall Street. Prior to Merrill Lynch, Saira worked in M&A and Restructuring at Wasserstein Perella.

Saira is a recognized thought leader on public-private alliances and is frequently called upon as a speaker. She serves on the Industry Advisory Board of the Michael J Fox Foundation for Parkinson's Research, the Board of the American Liver Foundation and as a Special Advisor to the California Institute for Regenerative Medicine.

Saira has a B.A. in Economics with Honors and Distinction from Stanford University where she graduated Phi Beta Kappa, and advanced degrees in Management Science & Engineering and Management Studies from Stanford University and the University of Cambridge. She currently serves on the Advisory Council for the Cambridge Judge Business School and was recently named to the Silicon Valley/San Jose Business Journal's 40 under 40 list.

Samuel Young, Research Group Leader, Molecular Mechanisms of Synaptic Function,
Max Plank Florida Institute

Dr Samuel Young's profile will be online shortly.

Sanjeev Munshi, Director in External Research and Licensing, Merck & Co.

Sanjeev Munshi

Dr Sanjeev Munshi's is a Director in the External Research and Licensing organization of the Merck Research Laboratories. Sanjeev's role is to identify partnering opportunities that fit with Merck's strategic research and development goals across all therapeutic and technology areas. Sanjeev is primarily responsible for scouting and managing alliances in the Southeastern and Mid-Atlantic US.

Sanjeev earned his Ph.D. in molecular biophysics (structural biology) from Indian Institute of Science, India and MBA from Villanova School of Business. Following a postdoctoral fellowship in structural virology at Purdue University, Sanjeev joined MRL at West Point, in 1995. After fifteen years of preclinical drug discovery research, Sanjeev moved into External Scientific Affairs in 2010. Sanjeev is based in Chapel Hill, North Carolina.

Semyon Kogan, President and COO, GEN3 Partners

Semyon Kogan's profile will be online shortly.

Sharon Mates, Founder, Chairman and CEO, Intra-Cellular Therapies

Sharon Mates

Sharon Mates is the Chairman and Chief Executive Officer of Intra-Cellular Therapies, Inc., a company focusing on the development of new drugs for psychiatric and neurodegenerative diseases, including schizophrenia, depression, bi-polar disorder, autism, Parkinson’s disease and Alzheimer’s disease. Dr. Mates has over 23 years of experience in the biotechnology industry ranging from founding several start-up ventures to leading a publicly traded company. From 1989 - 1998 Dr. Mates was the President of North American Vaccine and its predecessor companies. From 1998 to 2002 Dr. Mates was involved in founding several biotech companies. In 2002, along with Dr. Paul Greengard, Vincent Astor Professor (Nobel Laureate 2000), Moshe Alafi and Dr. Allen Fienberg, Dr. Mates founded Intra-Cellular Therapies Inc. Dr. Mates recently completed a two-year chairmanship of the Board of the New York Biotechnology Association and serves on the NYBA Board, along with other board memberships. Prior to her role in the biotechnology industry, Dr. Mates spent several years as a research analyst and an investment banker.

Dr. Mates received her Ph.D. from the University of Washington and was a fellow and post-doctoral fellow at the Massachusetts General Hospital and at the Harvard Medical School.

Sheila Menzies, Scientific Program Officer, Prize4Life

Sheila Menzies' profile will be online shortly.

Sheridan G. Synder, Chairman, President and CEO, Biocatalyst International

sheridan G synder

Sheridan G. Snyder is an entrepreneur with over forty years of experience, and a major figure in today's biotechnology industry.

Mr. Snyder graduated from the University of Virginia in 1958 with a BA, majoring in Romance Languages. His first company was Cambridge Mailing Machines, in 1964 that manufactures high speed envelope inserting machines.

Since then Mr. Snyder has subsequently founded 13 companies. These include Genzyme, based in Cambridge , Massachusetts , which now has a market cap of over $18 billion. Mr. Snyder's most recent venture was Upstate, a biotechnology company based in Charlottesville , Virginia which was recently sold to Serologicals Corp.

In 1971 Mr. Snyder also founded a packaging company, Instapak, which markets a new form of industrial packaging whereby liquid urethane is injected into a package and expands to 120 times its original volume in 15 seconds to form a complete protective barrier for heavy, fragile, technical equipment. It is now the largest division of Sealed Air Corp.

Biocatalyst International is the most recent of Mr. Snyder's business enterprises. It was founded with Mr. Snyder's vision of bridging the gap between countries that have brilliant science and the United States.

Sophia Colamarino, Consulting Associate Professor in the Department of Psychiatry and Behavioral Sciences, Stanford University

Sophia Colamarino

Sophia Colamarino is a Consulting Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University Medical School where she works in the Packard Autism Center at Stanford Children’s Hospital. Dr. Colamarino also consults for a variety of non-profit organizations regarding research investment opportunities and currently serves as the Director for Science and Health Programs for the John and Marcia Goldman Foundation.

Dr. Colamarino joined the non-profit research organization Cure Autism Now in November 2004 as Science Program Director prior to its merger with Autism Speaks, where she remained as Vice President of Research until 2011. During her tenure at Autism Speaks, the world's largest autism science and advocacy organization, she managed Autism Speaks’ Biology Division and developed several important research initiatives, including new efforts in neuropathology, innovative technology and translational biology. A recognized thought leader in the autism space, she also spends much of her time providing science lectures for the autism community. In 2008, Dr. Colamarino spearheaded development of an open access policy for publications resulting from Autism Speaks’ funded research, the first such policy for a US advocacy organization, for which she testified to Congress and has been appointed to the national advisory committee of the NIH's PubMed Central science archive.

Dr. Colamarino graduated with dual degrees in Biological Sciences and Psychology from Stanford University. She received her PhD in Neurosciences from the University of California, San Francisco, where she studied brain development with neuroscientist Marc Tessier-Lavigne, PhD. After receiving her PhD, Dr. Colamarino conducted research on the genetic disorder Kallmann Syndrome at the Telethon Institute for Genetics and Medicine in Milan, Italy, led by human geneticist Andrea Ballabio, MD. She then returned to the US to work at the Salk Institute in La Jolla, CA, studying adult neural stem cells and brain regeneration in the laboratory of stem cell pioneer Fred H. Gage, PhD.

Stan Yakatan, Chairman, Katan Associates

Stan Yakatan's profile will be online shortly.

Stephanie Leouzon, Senior Advisor, Torreya Partners

Stephanie Leouzon's profile will be online shortly.

Steven Xanthoudakis, Director, Licensing and External Research - Canada, Merck Canada Inc.

Steven Xanthoudakis' profile will be online shortly.

Sushma Selvarajan, Head of Business Development & Strategy, Roche Molecular Systems

Sushma Selvarajan's profile will be online shortly.

Todd Lynch, CFO, Metabolon, Inc.

Todd Lynch's profile will be online shortly.

Ted M Ross, Associate Professor, Department of Microbiology and Molecular Genetics, University of Pittsburgh

Ted Ross

Dr Ted M Ross is an Associate Professor in the Center for Vaccine Research and the Department of Microbiology and Molecular Genetics. He received his PhD in Microbiology and Immunology from Vanderbilt University in 1996. He trained in HIV/AIDS and Vaccine Development and Immunology at Duke and Emory Universities. He is a member of the Molecular Virology and Microbiology and Immunology graduate programs. His research focuses on understanding the mechanisms and development of effective vaccine design for infectious agents. Designing and developing vaccines for licensing and clinical trials.

Thomas Johnston, Chief Business Officer, Mucosis BV

Thomas Johnston's profile will be online shortly.

Valerie Landrio McDevitt, Assistant Vice President Division of Patents and Licensing,
University of South Florida

Valerie Landrio McDevitt

Valerie Landrio McDevitt is a U.S. registered patent attorney and Assistant Vice President at the University of South Florida Division of Patents and Licensing, which acts as the main university contact for industry partners and start-up companies interested in technology transfer. In 2010 USF was ranked 20th among technology transfer offices in licensing revenue and 9th among universities for US patents issued. During her almost ten year tenure at USF there has been significant improvement and advancement in licensing, revenue, and commercialization of early stage technology. Valerie was appointed by Governor Crist and served on the Task Force for the study of Biotech Competitiveness and currently sits on the USPTO’s Patents Public Advisory Committee.

Prior to joining USF, Valerie served as assistant patent counsel and a research chemist for Bausch & Lomb Pharmaceuticals. She also participated in the American Association for the Advancement of Science Fellowship program and worked as a science advisor with a House subcommittee in Washington, D.C.

In addition to her JD degree, Valerie holds a BS and MST in Chemistry, is a certified licensing professional through LES, a member of the Georgia and Florida bars, and admitted to practice before the Federal Patent and Trademark Office.

Yuji Iizawa, Vice President, Takeda Research Investment

Yuji Iizawa

Yuji Iizawa's joined Takeda Ventures, Inc. (TVI) as Vice President in April 2011 with more than 28 years R&D experience at Takeda. Yuji is focusing on investments in early stage bio-ventures with therapeutics and platform technologies. Prior to joining TVI, Yuji was Senior Director of Strategic Research Planning Department and Global Research Management Department in Pharmaceutical Research Division, Takeda Pharmaceutical Company, with responsibility for the strategic oversight of Takeda research affiliates Worldwide. Prior to this, Yuji spent 2 years with TVI when it was Takeda Research Investment, Inc. During his tenure in Takeda’s Pharmacology Research Laboratories, he assumed responsibility for drug discovery in infectious disease area such as antibacterial agents and anti-viral agents including anti-HIV drug, and spent one year on sabbatical in the Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, where Yuji studied cytokine responses in Listeria monocytogenes infection. Yuji joined Takeda in 1983 with a D.V.M. from Tokyo University, obtaining his Ph.D. from the same institution in 1990 by the research on efficacy of recombinant human interleukin 2 in experimental infection with Klebsiella pneumoniae.


 

 
  Meeting Guide
SPI2012 Guide
Click here to view the
SPI 2012 Conference Guide
 
  Meeting Scheduler >
Bio Partner
breakers palm beach
 
To learn more about presenting, exhibition or sponsorship opportunities, please contact Zoe Harris
+ 44 (0)203 463 4890 or by email: Zoe Harris.
  Venue: Details >
palm beah convention center
palm beach convention center
 
  Accommodation:
  Details >
breakers palm beach
breakers hotel palm beach
 
Sachs Associates provides VISA Support for attendees, please contact Zoe Harris
+ 44 (0)203 463 4890 or by email: Zoe Harris.
 
  Associated Companies  
Host Sponsor Gold Sponsor AEC Biominas Katan Novartis DSM Biologics LISA Swiss Biotech Association RX Communications Inovio Torreya GPI La Voie College Hill